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Abstract 
In this independent, multicenter, retrospective study, we investigated the short-term 
persistence to treatment with first-line self-injectable or oral disease-modifying treatments 
(DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly 
attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were 
collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore 
reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation 
over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 
women, 543 men); 374 (20.4%) of them discontinued the prescribed DMT after a median 
time of 6 months (range 3 days to 11.5 months) due to poor tolerability (n = 163; 43.6%), 
disease activity (n = 95; 25.4%), adverse events (n = 64; 17.1%), convenience (i.e. availability 
of new drug formulations) and pregnancy planning (n = 21; 1.1%). Although the proportion 
of discontinuers was higher with self-injectable (n = 107; 22.9%) than with oral DMT (n = 
215; 16.4%), the Cox regression model revealed no significant between-group difference (p 
= 0.12). Female sex [hazard ratio (HR) = 1.39, p = 0.01] and previous exposure to ≥ 3 DMTs 
(HR = 1.71, p = 0.009) were two independent risk factors for treatment discontinuation, 
regardless of prescribed DMTs. Our study confirms that persistence to treatment represents 
a clinical challenge, irrespective of the route of administration. 
 
Introduction 
Self-injectable disease-modifying treatments (DMTs)—glatiramer acetate and interferon 
beta—were, until recently, the only first-line therapies approved for relapsing–remitting 
multiple sclerosis (RRMS). In the pivotal clinical trials, the rates of DMT persistence at the 
end of first year on study ranged from 90 to 97% [1–4]. However, these results cannot be 
adequately extrapolated to the real-world population, as lower rates of treatment 
persistence have been reported in post-marketing real-world studies, ranging from 78.5 to 
90% after 1 year and dropping to 59–72% between the third and fifth year of treatment [5–
8]. Indeed, “old” injectable DMTs suffered from a low adherence and a high rate of dis-
continuations due to poor tolerance or convenience, or even to “forgetfulness” [9, 10]. 
Moreover, in real-world practice the presence of comorbidities can also affect persistence 
to treatment, leading to more frequent therapy changes [11]. 
 
In recent years, there has been an increasing availability of DMTs in RRMS, including two 
oral drugs—teriflunomide and dimethyl fumarate—available in Italy since 2014. Their 
indication is similar to self-injectable first-line DMTs [12–14], but the common perception is 
that these first-line oral DMTs may be more accepted and tolerated by patients than self-
injectable ones, merely due to their simpler route of administration. Patients with RRMS, 
indeed, express preferences for oral DMTs even when reasonably satisfied of their ongoing 
injective therapy [15]. Therefore, oral DMTs are expected to enhance treatment adherence, 
a key factor to reduce relapse rate, delay disability worsening and lead to better clinical 
outcomes [16]. However, oral DMTs are also associated with systemic side effects. Recently, 
persistence to oral DMTs was explored in two studies conducted in different countries (US 
and Italy), showing a discontinuation rate of 20–40% over 1 year of follow-up in patients 
treated with teriflunomide and dimethyl fumarate, mainly due to side effects [17, 18]. 
Consequently, there is no established evidence yet that oral DMTs are superior to self-
injectable ones in terms of adherence and persistence to treatment. 
 
In this multicenter retrospective study, we analyzed treatment persistence in a large cohort 
of patients with RRMS who started a first-line DMT in 2015, with the objective to evaluate 
and to compare treatment persistence between self-injectable and oral DMTs and to 
analyze possible predictors of discontinuation. 
 
Methods 
Study design 
This was an independent, multicenter, post-marketing study based on a retrospective 
analysis of data collected from patients with RRMS attending 21 tertiary outpatient MS 
Centres in Italy. Patients were considered eligible if they started a platform therapy with 
self-injectable or oral first-line DMTs from January to December 2015 and had at least 
12 months of follow-up. 
 
We considered the following DMTs: subcutaneous (sc), glatiramer acetate 20 mg, once daily 
or 40 mg every other day (Copaxone 20 or 40); intramuscular (im) interferon beta (IFNB)-1a 
30 mcg, once weekly (Avonex); sc pegylated IFNB-1a 125 mcg, every 2 weeks (Plegridy); sc 
IFNB-1b 250 mcg, every other day (Betaferon, Extavia); sc IFNB-1a 22 or 44 mcg, thrice per 
week (Rebif 22 or 44); oral teriflunomide 14 mg, once daily (Aubagio); oral gastro-resistant 
dimethyl fumarate 240 mg, twice daily (Tecfidera). 
 
We included data of both patients who started for the first time a DMT (naives) and those 
who switched from another first-line DMT (switchers), regardless of the reason for switching 
treatment. 
 
We excluded patients who started monoclonal antibod-ies (natalizumab and alemtuzumab) 
and fingolimod because their indication mainly encompasses patients failing a previous first-
line DMT and, therefore, this was considered as a “second-line” treatment strategy going 
beyond the scope of the study. Patients with disease course other than RRMS were also 
excluded. 
 
Data collection and harmonization 
In September 2016, clinicians from each participating Clinical Centre convened to a 
workshop in Rome where an ‘ad hoc’ shared electronic spreadsheet was created to collect 
clinical data for analyses. This electronic spreadsheet was further refined in another 
workshop held in January 2017 in Rome. Finally, an external subject collected data from 
each Centre until June 2017 and data were centrally reviewed for discrepancies by the two 
lead authors in September 2017. Regarding homogeneity of data collection, participating 
centers were all specialized MS clinics in hospital or University settings, whose neurologists 
were part of a scientific board called RIREMS (Raising Italian Researchers in MS) that gathers 
at least twice per year, since 2008, to discuss scientific and medical care issues of MS 
patients, with the objective of harmonizing the standard of care to patients across Italian 
MS Centres [19]. 
 
The present study was conducted in accordance with specific national laws and the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments. Given its 
retrospective design, in no way this study did interfere with the care received by patients 
 
Outcome definition 
The main outcome measure was treatment discontinuation within a follow-up period of 
12 months. 
 
Reasons for discontinuation were also collected and categorized into four groups: 
1. poor tolerability, i.e., when discontinuation was ‘patient-driven’ due to expected side 
effects; 
2. adverse events, i.e., when discontinuation was ‘physician-driven’ due to medical concern 
for expected or unexpected side effects; 
3. disease activity, i.e., radiological or clinical events that led physicians to discontinue 
treatment for lack of efficacy; 
4. others, i.e., any reason not included in the previous definitions. 
 
Research questions 
Question no. 1: “did the short-term persistence to treatment differ in patients treated with 
first-line self-injectable or oral DMTs?”. To answer this question, we compared the 
proportions of patients discontinuing a self-injectable or an oral DMT, without any specific 
distinction across drugs. There-fore, we collapsed Copaxone, Avonex, Plegridy, Betaferon, 
Extavia, Rebif into a single group (self-injectable DMTs) and Aubagio and Tecfidera into 
another group (first-line oral DMTs). 
 
Question no. 2: “was there any specific DMT associated with an increased risk of treatment 
discontinuation in the short-term period?”. To answer this question, we conducted a post 
hoc analysis to compare the proportions of patients discontinuing Copaxone, Avonex, 
Plegridy, Betaferon/Extavia/Rebif, Aubagio, and Tecfidera. This allowed us to explore if 
factors other than the administration route, such as treatment schedule or DMT-specific 
side effects, could affect the short-term treatment persistence. 
 
Question no. 3: “did the short-term persistence to treatment differ in naives patients and in 
switchers?”. To answer this question, we re-ran all the aforementioned analyses after 
splitting the whole sample into two subgroups (naives and switchers). 
Question no. 4: “were there demographic and/or clinical variables associated with an 
increased risk of treatment discontinuation in the short-term period?” To answer this 
question, we explored baseline demographic and clinical variables associated with 
treatment discontinuation, independent of the prescribed DMTs. 
 
Statistical analysis 
All research questions were explored in time-to-event analyses. We considered as main time 
variable the interval (in weeks) elapsed between treatment start (baseline) and treatment 
discontinuation for patients reaching the outcome, while all the other patients were right 
censored at 12 months (52 weeks). 
 
Cox proportional hazard regressions, adjusted for gender, age, time since first symptom, 
EDSS score and number of previously taken DMTs were built to compare self-injectable 
versus oral treatments (first question), different specific treatments (second question) and 
naives versus switchers (third question). Another Cox model was built to identify predictors 
for reaching the outcome by entering the afore-mentioned patients’ characteristics as 
covariates and the treatment as variable of no interest (fourth question). 
All models were stratified by Centre to correct for different prescription habits and rules, 
taking into account dis-parity across different regions in Italy in terms of treatment 
availability due to administrative issues. 
 
Results 
Participants 
We analyzed data of 1832 consecutive patients (1289 women, 543 men) with a mean age of 
40.0 (11.2) years, mean time since first symptoms of 9.1 (8.1) years and median EDSS score 
of 2.0 [0–7.5]. Out of 1832, 626 (34.2%) patients were treatment naïve, while the remaining 
1206 (65.8%) were switchers. As expected, naives were younger, had a shorter time since 
first symptom and lower EDSS score than switchers (p < 0.001). 
 
The most frequently prescribed treatment was Tecfidera (n = 1046; 57.1%), followed by 
Aubagio (n = 277; 15.1%); Copaxone 20 or 40 mg (n = 173; 9.4%); Betaferon, Extavia, Rebif 
22 or 44 mcg (n = 163; 8.9%); Avonex (n = 102; 5.6%); and Plegridy (n = 71; 3.9%). 
 
Outcome 
A total of 374 (20.4%) patients discontinued the prescribed DMT after a median time of 
6 months [ranging from 3 days to 11.5 months; see also Fig. 1] due to poor tolerability (n = 
163; 43.6%), disease activity (n = 95; 25.4%), adverse events (n = 64; 17.1%—see also 
Table 1 for details) and other reasons (n = 52; 2.8%) that included convenience (i.e., 
availability of new drug formulations, such as witch from Copaxone 20–40 mg and from 
Avonex to Plegridy—n = 31; 1.7%) and pregnancy planning (n = 21; 1.1%). 
 
To conform with our primary study purpose, that was to investigate persistence to 
treatment in 12 months period, we excluded from further analyses those patients who 
discontinued treatment for convenience and pregnancy planning (n = 52). These latter two 
situations cannot be indeed considered properly as two reasons of short persistence to 
treatment. Therefore, the next analyses are based on an overall sample of 1780 patients of 
whom 322 were discontinuers. Notably, time to discontinuation differed according to rea-
sons for discontinuation, as shown in Fig. 2. In more detail, discontinuation due to persistent 
disease activity occurred later than discontinuation due to either adverse events or poor 
tolerability (p < 0.001 by the log-rank test). 
 
 
 
Fig. 1 Kaplan–Meier curve showing time to treatment discontinuation in the whole study 
sample (n = 1832) 
 
Table 1 Frequency of adverse events leading to treatment discontinuation 
 
Answer no. 1 
Overall, we analyzed data of 468 patients who started a self-injectable DMT and 1312 who 
started an oral DMT. Although the proportion of discontinuers was higher with self-
injectable (n = 107; 22.9%) than with oral DMT (n = 215; 16.4%), the Cox regression model 
revealed no significant between-group difference (hazard ratio [HR] = 0.81; 95% confidence 
intervals [CIs] 0.62–1.05; p = 0.12). Figure 3 shows the survival graph according to group 
assignment. Different route of administration was associated with different reasons for 
discontinuation (Fig. 4a), poor tolerability being more common in patients treated with self-
injectable DMT and adverse events more common in patients treated with oral drugs (p = 
0.015 by the Chi-squared test). Discontinuation due to disease activity did not differ 
between self-injectable and oral DMTs. 
 
 
 
Fig. 2 Kaplan–Meier curves showing time to treatment discontinuation in patients who 
interrupted the prescribed disease-modifying treatment (n = 322), according to reasons for 
discontinuation 
 
Answer no. 2 
The highest discontinuation rate was observed in patients treated with Plegridy (45.1%) 
than with all the other DMTs, whose discontinuation rates ranged from 15.6 to 19.6% (p < 
0.001 by the Chisquared test; see also Fig. 5). The Cox regression model revealed a more 
than doubled-increased risk of treatment discontinuation with Plegridy when compared 
with Tecfidera, which was the DMT with the lowest discontinuation rate (see also Table 2). 
Reasons for discontinuation were significantly different across different types of DMT (p = 
0.008 by the Chi-squared test; see also Fig. 4b). 
 
 
 
Fig. 3 Kaplan–Meier curves showing time to treatment discontinuation in patients who 
started a self-injectable (n = 468) and in those who started an oral disease-modifying 
treatment (n = 1312) 
 
 
Fig. 4 Reasons for discontinuation of the prescribed disease-modifying treatment: a self-
injectable versus oral; b across different types of disease-modifying treatments; c naives 
versus switchers 
 
Answer no. 3 
We found no difference regarding short-term persistence to treatment in naïve patients 
versus switchers (HR = 1.14, 95% CIs 0.87–1.49; p = 0.35). Also reasons for discontinuation 
were not different between these two groups (p = 0.28; see also Fig. 4c). There was no 
difference between naïve patients and switchers even after considering each DMT 
separately, with the only exception for Tecfidera (p = 0.006 by the Chi-squared test). 
Tecfidera discontinuation for disease activity occurred indeed more frequently in naive 
patients (17/39; 43.6%) than in switchers (33/122; 27.0%). Accordingly, discontinuation for 
poor tolerability occurred more frequently in switchers (64/122; 52.5%) than in naïve 
patients (9/39; 23.1%). 
 
 
 
Fig. 5 Discontinuation rates according to different types of disease-modifying treatments 
 
Table 2 Cox proportional hazard regression model comparing the risk of treatment 
discontinuation across different types of disease-modifying treatments (n = 1780) 
 
 
Stratified by MS Clinics and adjusted for sex, age, time since first symptom, EDSS score, and 
no. of previously taken DMTs 
HR hazard ratio, 95% CIs 95% confidence intervals 
In bold are reported values significant at a two-sided α-level of 0.05 
 
Answer no. 4 
Female sex (HR = 1.39, p = 0.01) and previous exposure to ≥ 3 DMTs (HR = 1.71, p = 0.009) 
were two independent risk factors for treatment discontinuation, regardless of prescribed 
DMTs. Notably, reasons for discontinuation did not differ between women and men and 
between patients with prior exposure to ≥ 3 DMTs and those who received < 3 DTMs. We 
also found a statistical trend for a shorter persistence to treatment in patients with higher 
EDSS score (HR = 1.08, p = 0.06) (see also Table 3). 
 
Discussion 
In this multicenter study, we performed a retrospective observational analysis on a large 
cohort of patients with RRMS who began a first-line drug in 2015, to assess their short-term 
persistence after the availability of new oral drugs. 
 
The overall rate of discontinuation was approximately 20% at 12 months, mainly for poor 
tolerability (> 40%). This prevalence is higher than expected from RCTs and shows the 
evident differences between the “ideal” experimental setting and the real-world practice. 
Moreover, we observed longer time to discontinuation for disease activity than for adverse 
events and poor tolerability. These data seem to reflect the longer follow-up necessary to 
assess DMT effectiveness in clinical practice, since most DMTs show a certain latency before 
being considered active, requiring a “re-baseline” several months after treatment initiation 
[20]. On the other hand, poor tolerability is typically an immediate complication leading to 
early discontinuation. 
 
Table 3 Cox proportional hazard regression model showing variables associated with an 
increased risk for treatment discontinuation (n = 1780) 
 
 
Stratified by disease characteristics and adjusted for DMT categories HR hazard ratio, 95% 
CIs 95% confidence intervals 
In bold are reported values significant at a two-sided α-level of 0.05 
 
Through our analysis, we answered to four main research questions: first, we found no 
differences in persistence to the self-injectable DMTs and the new oral ones. However, 
different routes of administration were associated with different reasons for 
discontinuation, with poor tolerability being by far the main obstacle in MS therapy with 
self-injectable DMTs. Of note, oral DMT suffered from more adverse events, while 
discontinuation rates due to disease activity were similar within the two categories, these 
results are somewhat surprising since clinicians and patients generally anticipate greater 
persistence to treatment with oral than injectable DMTs. However, the better tolerability of 
oral DMTs seems to be counter parted by the more frequent adverse events (and similar 
efficacy) compared to self-injectable DMTs, at least in the short term. We must admit that 
modern treatments are burdened by more unexpected adverse events and less confidence 
in their management by neurologists, due to the relatively short experience matured by MS 
specialists. Hopefully, with the enlarging of real-life experience, adverse events will be 
better taken in charge and even avoided, leading to better persistence. Moreover, our study 
suggests a similar impact on clinical activity in the short term, but this specific finding should 
be interpreted with caution since our study was not designed to assess short-term 
effectiveness, due to the absence of MRI data and different time of efficacy latency of the 
various DMTs.  
 
The second question regarded differences in discontinuation among drugs: we found the 
highest discontinuation rate in patients treated with Plegridy, with a more than doubled-
increased risk when compared with Tecfidera, which showed the lowest discontinuation 
rate. Reasons for discontinuation were significantly different also across different types of 
DMTs, with interferons being poorly tolerated, Copaxone burdened by a relatively higher 
rate of discontinuation for poor efficacy, and the two oral DMTs sharing the same dis-
continuation profile. Although the small subgroup sample size does not allow to draw 
definitive conclusions on effectiveness, the poor tolerability of Plegridy seems to emerge 
unequivocally, confirming the notion that it is associated with flu-like reactions and local 
side effects, ranging from pruritus to pain, edema and erythema in 66% of patients, despite 
its proven safety and effectiveness [21]. 
 
The third question was related to the possible difference regarding short-term persistence 
to treatment in naïve patients versus switchers. We found no differences in both 
discontinuation rates and reasons for discontinuation, with the only exception for Tecfidera 
being the discontinuation rate for disease activity more frequent in naives than in switchers, 
while discontinuation for poor tolerability occurred more frequently in switchers than in 
naïves. This likely reflects the fact that naïve patients starting Tecfidera had a more active 
disease at treatment initiation, maybe due to a perceived better efficacy of this drug 
compared to other first-line options [22]. 
 
Eventually, our aim was to identify predictors of treatment discontinuation. Several studies 
tried to identify patients at risk of discontinuation, with conflicting results. In our cohort, 
female sex and previous exposure to more than two DMTs were two independent risk 
factors for treatment discontinuation, regardless of prescribed DMTs and in the absence of 
differences for reasons for discontinuation. We also found a trend for a shorter persistence 
to treatment in patients with higher EDSS score. Regarding gender differences, it has been 
already shown that female subjects with MS experience poorer persistence to treatment 
[16], and tolerate less local effects of interferon injections [23]. The reduced persistence to 
treatment in patients who already changed more than two therapies might have different 
interpretations: it might depend on either a more aggressive form of disease, with frequent 
switches due to poor efficacy, or to an individual predisposition to poor tolerability. The 
trend towards more frequent discontinuations in patients with higher EDSS is an expected 
result, since it was already observed in several studies [24, 25]; this latter finding may be 
explained, in our opinion, by a more “aggressive” therapeutic attitude of MS specialists, who 
are concerned about disability accrual in patients with worse baseline disability, leading to 
frequent switches to more active drugs. In our report, these data did not reach statistical 
significance probably because discontinuation for persistent clinical activity requires longer 
time than for poor tolerability or even side effects, as already discussed. 
 
We acknowledge that our study suffers from some limitations due to the real-life setting, 
such as absence of data on baseline radiological characteristics (that might have influenced 
treatment choice), non-homogeneity of recruitment in different Centres and obviously 
different behaviors of clinicians, since the definition of reasons for discontinuation was 
based on the neurologist opinion. Furthermore, the higher number of patients starting 
Tecfidera and, to a lesser extent, Teriflunomide, likely reflects the recent availability of these 
new DMTs and we cannot exclude that prescription habits are changing in the next years. 
However, real-world data are necessary to analyze large number of patients, not pre-
selected as in trials, and to provide more generalizable and useful information to help 
clinicians for decision-process making in clinical practice. 
 
In conclusion, our study adds valuable information of short-term persistence to first-line 
DMTs in the contemporary era. We found an approximately 20% discontinuation rate over 
12 months, with a similar persistence to self-injectables and oral DMTs, the first poorly 
tolerated but the second ones burdened by more frequent adverse events. Research should 
be aimed at improving tolerability of self-injectable DMTs, through molecular structure 
modifications or device development, and to reduce adverse event risk related to  
oral DMTs, by improving safety and follow-up procedures, and by defining patients’ 
individual risk, since persistence to treatment still represents a clinical challenge, 
irrespective of the route of administration. 
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